About Chime Biologics Limited
Chime Biologics Limited is a global contract development and manufacturing organisation, a CDMO specialised in biologics, with its development and manufacturing campus in Wuhan and innovation hubs in Shanghai and Basel. Its official website, in English, presents it with more than seven hundred employees and with the mission of making innovative biologics and biosimilars more affordable and accessible to patients worldwide.
Its integrated platform covers the whole biologics cycle: cell line development, process development and transfer, protein science and characterisation, quality control and assurance, clinical and commercial manufacturing of drug substance and drug product, materials management and international regulatory support. It works with monoclonal and bispecific antibodies, fusion proteins, conjugated proteins, enzymes and vaccines.
The company operates the world's first modular biopharmaceutical factory based on single-use technology and built to international good manufacturing practice standards. In the biotechnology and laboratory category, Chime provides the profile of an industrial partner enabling biotech companies from many countries to take their molecules from the laboratory to the market with controlled timelines and costs.
Its integrated platform covers the whole biologics cycle: cell line development, process development and transfer, protein science and characterisation, quality control and assurance, clinical and commercial manufacturing of drug substance and drug product, materials management and international regulatory support. It works with monoclonal and bispecific antibodies, fusion proteins, conjugated proteins, enzymes and vaccines.
The company operates the world's first modular biopharmaceutical factory based on single-use technology and built to international good manufacturing practice standards. In the biotechnology and laboratory category, Chime provides the profile of an industrial partner enabling biotech companies from many countries to take their molecules from the laboratory to the market with controlled timelines and costs.